Elevated sRAGE levels predict mechanical ventilation need in moderate to severe COVID-19 pneumonia patients
Background
Severe respiratory failure is a critical complication of SARS-CoV-2 infection, often necessitating mechanical ventilation (MV), which is associated with poorer outcomes. Identifying patients at high risk for MV early could enable proactive interventions and optimize resource allocation. Current clinical assessments alone may not fully capture the evolving lung injury. This study investigates whether specific soluble biomarkers of bronchoalveolar epithelial and endothelial injury can reliably predict MV requirement in COVID-19 pneumonia.
Study Design
This prospective, observational, monocentric cohort study enrolled 54 COVID-19 patients with pneumonia within 48 h of hospital admission. Researchers measured serum concentrations of five bronchoalveolar injury biomarkers: Krebs von den Lungen-6 (KL-6), soluble receptor for advanced glycation end-products (sRAGE), club cell protein 16 (CC16), angiopoietin-2 (Ang-2), and soluble CD146 (sCD146) at Day 0, 7, and 14 using ELISA assays. The primary endpoint was the need for mechanical ventilation during hospitalization.
Results
Of the 54 enrolled patients, 23 (43%) required mechanical ventilation (MV), 13 (24%) high flow oxygen therapy (HFOT), and 18 (33%) standard oxygen. At inclusion (Day 0), levels of KL-6, sRAGE, and CC16 were significantly higher in MV patients compared to non-MV patients (p < 0.05). sRAGE showed the most pronounced difference, with a 2.4-fold increase in MV patients. In multivariate logistic regression, sRAGE and SpO2/FIO2 were identified as independent risk factors for MV. For every 1000 pg/mL increase in sRAGE, the odds of requiring MV increased by 1.316 (95% CI [1.040-1.667]; p = 0.022).
Patients with an
sRAGElevel ≥ 5449 pg/mL at inclusion had a significantly lower probability of weaning from oxygen at Day 60 (HR 0.36; 95% CI [0.19-0.67]; p = 0.001). Furthermore, from Day 7 to Day 14,CC16levels increased whilesCD146levels decreased in MV patients, indicating distinct kinetic profiles.
Key Findings
- Serum
sRAGE,KL-6, andCC16levels were significantly higher in COVID-19 patients requiring mechanical ventilation at hospital admission. sRAGEshowed a 2.4-fold increase in MV patients compared to non-MV patients.- In multivariate analysis,
sRAGE(OR 1.316 per 1000 pg/mL increase; p = 0.022) was an independent predictor for mechanical ventilation. - Patients with
sRAGE≥ 5449 pg/mL at inclusion had a 64% lower probability of weaning from oxygen by Day 60 (HR 0.36; p = 0.001).
Why It Matters
This study suggests that early measurement of serum sRAGE could serve as a crucial prognostic tool for clinicians managing moderate to severe COVID-19 pneumonia. Identifying patients at high risk for mechanical ventilation upon hospital admission allows for more aggressive monitoring, earlier escalation of care, or enrollment in targeted clinical trials. This could potentially improve patient outcomes by preventing severe respiratory deterioration and optimizing the allocation of intensive care resources. While not a direct intervention, incorporating sRAGE into existing clinical protocols could refine risk stratification and guide treatment strategies, moving towards more personalized care in acute respiratory distress.
covid-19
srage
biomarkers
mechanical-ventilation
pneumonia
respiratory-failure